ValuEngine upgraded shares of Viking Therapeutics (NASDAQ:VKTX) from a buy rating to a strong-buy rating in a research note released on Wednesday.
A number of other analysts also recently issued reports on VKTX. Maxim Group set a $8.00 price target on Viking Therapeutics and gave the stock a buy rating in a report on Thursday, May 10th. HC Wainwright set a $11.00 price target on Viking Therapeutics and gave the stock a buy rating in a report on Thursday, May 10th. Roth Capital set a $8.00 price target on Viking Therapeutics and gave the stock a buy rating in a report on Thursday, March 8th. BidaskClub downgraded Viking Therapeutics from a buy rating to a hold rating in a report on Friday, March 16th. Finally, William Blair began coverage on Viking Therapeutics in a report on Monday, April 30th. They set an outperform rating for the company. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $9.00.
Shares of Viking Therapeutics opened at $5.42 on Wednesday, according to MarketBeat. The stock has a market cap of $253.65 million, a price-to-earnings ratio of -6.86 and a beta of 2.10. Viking Therapeutics has a 1 year low of $0.88 and a 1 year high of $7.36.
Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.02. sell-side analysts predict that Viking Therapeutics will post -0.45 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Sio Capital Management LLC lifted its holdings in shares of Viking Therapeutics by 2.1% in the 1st quarter. Sio Capital Management LLC now owns 1,276,845 shares of the biotechnology company’s stock valued at $5,580,000 after purchasing an additional 26,595 shares during the last quarter. Granite Investment Partners LLC purchased a new stake in shares of Viking Therapeutics in the 1st quarter valued at about $140,000. Northern Trust Corp lifted its holdings in shares of Viking Therapeutics by 97.1% in the 1st quarter. Northern Trust Corp now owns 78,953 shares of the biotechnology company’s stock valued at $345,000 after purchasing an additional 38,901 shares during the last quarter. UBS Group AG lifted its holdings in shares of Viking Therapeutics by 533.3% in the 1st quarter. UBS Group AG now owns 63,329 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 53,329 shares during the last quarter. Finally, Creative Planning lifted its holdings in shares of Viking Therapeutics by 600.0% in the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 60,000 shares during the last quarter. 35.94% of the stock is owned by institutional investors and hedge funds.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.